Agenus Inc. (AGEN)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
6.12 USD
+2.77
(82.687%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.11 -0.01 (-0.009%) ⇩ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:39 a.m. EDT
The investment case here is fundamentally broken by a brutal multi-year decline. Despite the company reporting positive profit margins and strong revenue growth recently, the stock has lost over 92% of its value over the last nine years, with four consecutive years of negative annual returns ending just last year. This persistent price collapse suggests the market sees severe structural issues—likely related to the massive cash burn and negative book value—that outweigh the top-line growth. The balance sheet is precarious, with debt exceeding cash reserves and a current ratio below 0.4, creating a high risk of liquidity distress. Analysts are optimistic with a $15.50 target, but this ignores the reality that the business may be unable to sustain operations without further dilution or capital raises. On the short end, the stock is technically oversold but lacks the catalyst to reverse the trend immediately, while the options market is screaming 'sell' with heavy put positioning. There is no dividend to provide income, and the long-term outlook remains deeply bearish due to the deteriorating equity base and funding risks. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.178802 |
| AutoARIMA | 0.181728 |
| AutoETS | 0.181734 |
| AutoTheta | 0.268440 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 2.17 |
| Ljung-Box p | 0.670 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 16.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.742 |
| Market Cap | 254,851,680 |
| Trailing P/E | 2.99 |
| Forward P/E | -2.66 |
| Beta | 1.55 |
| Profit Margins | 52.16% |
| Website | https://www.agenusbio.com |
As of July 11, 2026, 4:39 a.m. EDT: Speculators are heavily positioning for downside protection with significant open interest in out-of-the-money puts expiring in late 2027 and early 2028, particularly at strikes well below the current price. While there is some call volume at higher strikes ($5-$10) suggesting a speculative hope for a recovery, the overwhelming weight of the options chain (over 90% of open interest in long-dated contracts) is concentrated in put structures, indicating a market consensus that the stock will likely trade lower before any potential rebound occurs.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.50951684 |
| Address1 | 3 Forbes Road |
| All Time High | 7,065.751 |
| All Time Low | 1.38 |
| Ask | 7.74 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,193,580 |
| Average Daily Volume3 Month | 870,254 |
| Average Volume | 870,254 |
| Average Volume10Days | 1,193,580 |
| Beta | 1.554 |
| Bid | 4.95 |
| Bid Size | 2 |
| Book Value | -5.743 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,672,444,800 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.12 |
| Current Ratio | 0.382 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 8.7 |
| Day Low | 4.91 |
| Display Name | Agenus |
| Earnings Call Timestamp End | 1,747,053,000 |
| Earnings Call Timestamp Start | 1,747,053,000 |
| Earnings Timestamp | 1,778,502,600 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | 15,188,000 |
| Ebitda Margins | 0.12262 |
| Enterprise To Ebitda | 16.69 |
| Enterprise To Revenue | 2.046 |
| Enterprise Value | 253,484,736 |
| Eps Current Year | 0.5 |
| Eps Forward | -2.3 |
| Eps Trailing Twelve Months | 2.05 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 781 674 4200 |
| Fifty Day Average | 3.3516 |
| Fifty Day Average Change | 2.7684 |
| Fifty Day Average Change Percent | 0.82599354 |
| Fifty Two Week Change Percent | -50.951683 |
| Fifty Two Week High | 8.7 |
| Fifty Two Week High Change | -2.58 |
| Fifty Two Week High Change Percent | -0.29655173 |
| Fifty Two Week Low | 2.71 |
| Fifty Two Week Low Change | 3.4099998 |
| Fifty Two Week Low Change Percent | 1.2583025 |
| Fifty Two Week Range | 2.71 - 8.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 950,020,200,000 |
| Float Shares | 38,852,805 |
| Forward Eps | -2.3 |
| Forward P E | -2.6608696 |
| Free Cashflow | -53,024,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.97393 |
| Gross Profits | 120,637,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06723 |
| Held Percent Institutions | 0.23698999 |
| Implied Shares Outstanding | 41,642,431 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.agenusbio.com/investors/performance.shtml |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,880,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. |
| Long Name | Agenus Inc. |
| Market | us_market |
| Market Cap | 254,851,680 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_409956 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 64,391,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 139,502,143 |
| Number Of Analyst Opinions | 2 |
| Open | 5.4199 |
| Operating Cashflow | -87,527,000 |
| Operating Margins | 0.44623002 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.44 |
| Phone | 781 674 4400 |
| Post Market Change | -0.008699894 |
| Post Market Change Percent | -0.14215513 |
| Post Market Price | 6.1113 |
| Post Market Time | 1,783,987,197 |
| Previous Close | 3.35 |
| Price Eps Current Year | 12.24 |
| Price Hint | 2 |
| Price To Book | -1.0656451 |
| Price To Sales Trailing12 Months | 2.057479 |
| Profit Margins | 0.52159 |
| Quick Ratio | 0.357 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 2.77 |
| Regular Market Change Percent | 82.6866 |
| Regular Market Day High | 8.7 |
| Regular Market Day Low | 4.91 |
| Regular Market Day Range | 4.91 - 8.7 |
| Regular Market Open | 5.4199 |
| Regular Market Previous Close | 3.35 |
| Regular Market Price | 6.12 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 173,608,324 |
| Return On Assets | 0.02525 |
| Revenue Growth | 0.402 |
| Revenue Per Share | 3.742 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 41,642,431 |
| Shares Percent Shares Out | 0.144 |
| Shares Short | 5,994,778 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,464,046 |
| Short Name | Agenus Inc. |
| Short Percent Of Float | 0.1458 |
| Short Ratio | 7.13 |
| Source Interval | 15 |
| State | MA |
| Symbol | AGEN |
| Target High Price | 23.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 15.5 |
| Target Median Price | 15.5 |
| Total Cash | 34,996,000 |
| Total Cash Per Share | 0.84 |
| Total Debt | 41,074,000 |
| Total Revenue | 123,866,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.05 |
| Trailing P E | 2.9853659 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.63725 |
| Two Hundred Day Average Change | 2.48275 |
| Two Hundred Day Average Change Percent | 0.6825899 |
| Type Disp | Equity |
| Volume | 173,608,324 |
| Website | https://www.agenusbio.com |
| Zip | 02,421-7305 |